



www.mesoscale.com[®]

Ordering Information

MSD Customer Service
Phone: 1-240-314-2795
Fax: 1-301-990-2776
Email: CustomerService@mesoscale.com

Scientific Support

Phone: 1-240-314-2798
Email: ScientificSupport@mesoscale.com


Company Address

Meso Scale Discovery
A division of
Meso Scale Diagnostics, LLC.
1601 Research Boulevard
Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description
Multiplex	K151ACM, K251ACM	U-PLEX Metabolic Group 1 (human)
	K1516AK-1/-2/-4	U-PLEX Human PP Assay with SECTOR™ plates
Singleplex	K1516AK-21/-22/-24	U-PLEX Human PP Assay with QuickPlex Ultra™ plates
	K2516AK-2/-4	U-PLEX Human PP Assay with 384-well plates
Antibody Set	B216A-2/-3	U-PLEX Human PP Antibody Set
Protocol	U-PLEX Product Inserts are available at www.mesoscale.com	

The MESO SCALE DISCOVERY[®] U-PLEX platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX[®] Human PP Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)
PP	0.19	0.19-0.27

The Calibrator curve was fitted with a 4-parameter logistic model with a 1/Y² weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	1,240	3.9	7.6
Mid	162	3.7	100
Low	24	3.8	14.0

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

For Research Use Only.
Not for use in diagnostic procedures.

MSD® U-PLEX Human PP

Tested Samples

Sample Type	Serum (N=12)	EDTA Plasma (N=12)	P800 Plasma (N=8)
Median (pg/mL)	16	17	30
Range (pg/mL)	4.4-71	6.5-63	15-155
% Detected	100	100	100

Normal serum, EDTA plasma, and P800 plasma samples were diluted 4-fold prior to the assay.

Dilution Linearity

Serum			EDTA Plasma			P800 Plasma			Cell Culture Media		
Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
2	113	97-131	2	110	95-123	2	118	103-135	2	117	110-130
8	105	95-112	8	97	90-106	8	97	92-101	8	95	90-105
16	115	90-139	16	103	96-116	16	105	95-116	16	92	86-100

Normal human serum, EDTA plasma, P800 plasma, and cell culture media were spiked with Calibrator and tested at different dilutions. Percent recovery at each dilution level was normalized to the dilution-adjusted, 4-fold concentration. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

$$\% \text{ Recovery} = (\text{measured concentration} / \text{expected concentration}) \times 100$$

Spike Recovery

Spike Level	Serum		EDTA Plasma		P800 Plasma		Cell Culture Media	
	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	99	95-106	97	86-104	92	86-98	104	97-112
Mid	99	96-105	97	94-103	96	94-97	102	95-107
Low	99	94-104	100	94-107	95	91-99	105	97-111

Normal serum, EDTA plasma, P800 plasma, and cell culture media were spiked with Calibrator at 3 levels. Spiked samples were diluted 4-fold to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

$$\% \text{ Recovery} = (\text{measured concentration} / \text{expected concentration}) \times 100$$

Specificity

To assess specificity, the PP Antibody Set was tested individually against a larger panel of analytes for nonspecific binding (BAFF, BDNF, C-Peptide, CTACK, Desghrelin, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF-21, FGF-23, FLT3L, Fractalkine, FSH, G-CSF, Ghrelin (Ser3-octanoylated), GIP (1-42), GIP (3-42), GLP-1 (7-36), GLP-1 (9-36), GM-CSF, GRO- α , I-309, IFN- α 2a, IFN- β , IFN- γ , IL-1 α , IL-1 β , IL-1RA, IL-2, IL-2R α , IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN- λ 1, IL-31, IL-33, Insulin, IP-10, I-TAC, Leptin, LH, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1 α , MIP-1 β , MIP-5, PIGF, PP, Proinsulin, PYY (3-36), SDF-1 α , TNF- α , TNF- β , TPO, TRAIL, TSLP, VEGF-A, YKL-40, and β -NGF). Nonspecific binding was less than 2.0%.

$$\% \text{ Nonspecificity} = (\text{nonspecific signal} / \text{specific signal}) \times 100$$

Diluent Compatibility

The data included in this document were collected with Assay Diluent 13 (supplemented with 1,000 KIU/mL Aprotinin [provided] and 100 μ M diprotin A [not provided]) and Antibody Diluent 11. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested. Diprotin A should be purchased separately.

Assay Components

Calibrator: Pancreatic Polypeptide is included in Calibrator 13. The human PP Calibrator is a synthetic peptide.

Antibodies: The U-PLEX Human PP Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection.

Assay generation: A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.

